Researchers advance drugs that treat pain without addiction

Researchers advance drugs that treat pain without addiction

New therapies are using creative approaches that target the body’s sensory neurons, which send pain signals to the brain.

Neurocarrus

Opioids are one of the most common ways to treat pain. They can be effective but are also highly addictive, an issue that has fueled the ongoing opioid crisis. In 2020, an estimated 2.3 million Americans were dependent on prescription opioids.

Opioids bind to receptors at the end of nerve cells in the brain and body to prevent pain signals. In the process, they trigger endorphins, so the brain constantly craves more. There is a huge risk of addiction in patients using opioids for chronic long-term pain. Even patients using the drugs for acute short-term pain can become dependent on them.

Scientists have been looking for non-addictive drugs to target pain for over 30 years, but their attempts have been largely ineffective. “We desperately need alternatives for pain management,” says Stephen E. Nadeau, a professor of neurology at the University of Florida.

A “dimmer switch” for pain

Paul Blum is a professor of biological sciences at the University of Nebraska. He and his team at Neurocarrus have created a drug called N-001 for acute short-term pain. N-001 is made up of specially engineered bacterial proteins that target the body’s sensory neurons, which send pain signals to the brain. The proteins in N-001 turn down pain signals, but they’re too large to cross the blood-brain barrier, so they don’t trigger the release of endorphins. There is no chance of addiction.

Keep Reading Keep Reading
Sarah Philip
Sarah Philip is a London-based freelance journalist who writes about science, film and TV. You can follow her on Twitter @sarahph1lip.
A mix of intestinal viruses could help people stay healthy longer

Based on recent research, new therapies could promote a mix of viruses in the intestines to help prevent diseases of aging.

Adobe Stock

Story by Big Think

Our gut microbiome plays a substantial role in our health and well-being. Most research, however, focuses on bacteria, rather than the viruses that hide within them. Now, research from the University of Copenhagen, newly published in Nature Microbiology, found that people who live past age 100 have a greater diversity of bacteria-infecting viruses in their intestines than younger people. Furthermore, they found that the viruses are linked to changes in bacterial metabolism that may support mucosal integrity and resistance to pathogens.

Keep Reading Keep Reading
Peter Rogers
Dr. Peter Rogers grew up milking cows and building barns. This provided him the transferable skills necessary for a smooth transition into academic research. Three years of genetics research led to six years of immunology research, which led to a Ph.D. from Auburn University. That led to three and half years of instructional design research at Tufts University School of Medicine. His expertise includes biomedical sciences & technology, social determinants of health, bovine birthing, training & development, and cognitive psychology. He’s taught dozens of university courses, ranging from Principles of Biology to Advanced Medical Immunology. He is currently co-writing a book with his father, George Rogers, called "How to Correctly Hold a Flashlight: A Disagreement in Academic and Agricultural Perspectives."
Embrace the mess: how to choose which scientists to trust

A dozen bioethicists and researchers shared their advice on how to spot the scientists searching for the truth more than money, ego or fame.

Adobe Stock

It’s no easy task these days for people to pick the scientists they should follow. According to a recent poll by NORC at the University of Chicago, only 39 percent of Americans have a "great deal" of confidence in the scientific community. The finding is similar to Pew research last year showing that 29 percent of Americans have this level of confidence in medical scientists.

Not helping: All the money in science. Just 20 percent of Pew’s survey respondents think scientists are transparent about conflicts of interest with industry. While this issue is common to many fields, the recent gold rush to foot the bill for research on therapies for healthy aging may be contributing to the overall sense of distrust. “There’s a feeling that at some point, the FDA may actually designate aging as a disease,” said Pam Maher, a neuroscientist who studies aging at Salk Institute. “That may be another impetus for a lot of these companies to start up.”

But partnering with companies is an important incentive for researchers across biomedical fields. Many scientists – with and without financial ties and incentives – are honest, transparent and doing important, inspiring work. I asked more than a dozen bioethicists and researchers in aging how to spot the scientists who are searching for the truth more than money, ego or fame.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.